Search Results

10 results for population screening

The Use of Cell-free DNA in Clinical Practice: Work in Progress

DNA in test tubes and a doctor with a stethoscope

A recent review outlines the use of circulating tumor DNA (ctDNA) in clinical practice and the requirements necessary to extend the use of this technology for health impact. Cell-free DNA (cfDNA) is extracellular strands of DNA present in body fluids. Circulating tumor DNA (ctDNA) is a specific type of cfDNA that originates from a primary tumor, circulating

Posted on by Mindy Clyne, Katherine Kolor, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags ,

Preeclampsia, Genomics and Public Health

a doctor checking the blood pressure of a pregnant person

A recent study identified a cell free RNA (cfRNA) signature that was promising in predicting pre-eclampsia several weeks before the onset of symptoms. At 29 weeks pregnant, Erica was diagnosed with preeclampsia, a pregnancy complication marked by high blood pressure and signs of organ failure, most often liver or kidney damage. According to the Mayo

Posted on by Erica L. Dawson, Population Health Surveillance Branch, Division of Population Health, National Center on Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention; Muin J. Khoury, Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention3 CommentsTags

Trends in Tier 1 Genomic Applications 2013-2022

two figures looking at genomics trends with the text Tier 1 Applications

The CDC Tier 1 genomic applications database can help consumers, providers, health care organizations and public health programs accelerate the translation of genomic discoveries into improved population health.       Background Advances in genomics and precision medicine are proceeding at a rapid pace. Many genomic tests have reached clinical practice without clear indication as to whether their

Posted on by Mindy Clyne, W. David Dotson, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags ,

Measuring Lipoprotein(a) in Clinical Practice to Reduce the Burden of Cardiovascular Disease? Still Work in Progress.

lipoprotein in clinical setting

A recent review suggested that the use of lipoprotein (Lp) (a) measurement in clinical practice may have clinical and economic benefits for patients, healthcare systems, and society as a whole. However, widespread adoption of Lp(a) measurement in the general population has been hindered by limited treatment options targeting Lp(a) reduction. Cardiovascular disease (CVD) remains the

Posted on by Jeffery Osei, Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; Laurence S. Sperling, Million Hearts initiative, Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, and Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta Georgia; Ijeoma Isiadinso, Emory Center for Heart Disease Prevention, Division of Cardiology, Emory University School of Medicine, Atlanta Georgia; Ridgely Fisk Green, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta Georgia3 CommentsTags ,

Precision Health Innovations in the Pandemic Era

a line graph

Two recent articles, one in Nature Medicine and another in Nature Biotechnology, highlight areas of health innovation that have been accelerated by the COVID-19 pandemic. This blog post focuses on two precision health applications of technology—(1) genomics and (2) wearable devices and smartphone apps—that are likely to have a lasting impact beyond the pandemic. Increased

Posted on by Danielle Rasooly, Emily Drzymalla, and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention Atlanta, GeorgiaTags ,

Polygenic Risk Scores in Clinical Practice? Still Making the Case

a polygenic risk score curve with a double helix, a doctor pointing at a tablet with icons surround it, and a doctor talking to her patient

Two recent systematic reviews show the lack of data on clinical utility of polygenic risk scores and major challenges in implementation. The Promise of Polygenic Risk Scores in Population Health Many common diseases such as cancer, diabetes, and heart disease, result from the combination of genetic factors and physical and social environmental factors. Genome-wide association

Posted on by Jeffery Osei, Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; W. David Dotson, Marta Gwinn, Ridgely Fisk Green, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta GeorgiaTags , ,

Using Implementation Science Frameworks in Genomics and Precision Medicine: We Can Do Better!

data being held by a hand and hands putting together two puzzle pieces

A recent scoping review identified many structured approaches to the implementation of genomics and precision medicine and limited use of implementation science frameworks. With continuous advances in genomics and accelerated translation from discovery into clinical practice, in our blog posts, we have repeatedly examined the crucial importance and emerging role of implementation science in the

Posted on by Mindy Clyne, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia, David Chambers, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, and Muin J Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia

Rare Disease Day 2022: The Evolving Impact of Genomics and Precision Health

Rare Disease Day 2022 with a ribbon and a map of the world

In celebration of Rare Disease Day 2022, we reprint excerpts of four previous blogs. Rare Diseases, Genomics and Public Health: An Expanding Intersection (February 17, 2016) Rare Disease Day is celebrated on the last day of February each year. On that day, millions of patients and their families around the world share their stories in order

Posted on by Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags

Precision Public Health in Action: New CDC Pilot Projects Integrate Human Genomics into Public Health Surveillance and Applied Research

a magnifying glass looking at a globe with DNA

In collaboration with the CDC Office of Advanced Molecular Detection, we recently launched a new, five-year initiative to strengthen public health capacity by introducing elements of human genomics into both public health surveillance and applied research. We report here on the successful launch of one of the initiative’s components. The Office of Genomics and Precision Public

Posted on by Mindy Clyne, W. David Dotson, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags

Equitable Implementation of Cascade Testing for Genetic Disorders: Where are We?

a cascade testing pedigree with a scale and a figure with a magnifying glass looking at a question mark

Testing relatives of individuals with genetic disorders, a process known as cascade testing or cascade screening, is critical for identifying those needing health services that can prevent morbidity and mortality. Yet, cascade testing is poorly implemented in clinical practice. For example, there are several genetic conditions with CDC tier 1 evidence-based recommendations for cascade testing,

Posted on by Mindy Clyne, W. David Dotson, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags , ,